Belite Bio BLTE
United StatesHealthcare · BiotechnologyUSD
228.89 USD (+46.6%)
9 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Belite Bio is a clinical-stage biopharmaceutical company focused on developing therapies for retinal diseases, such as geographic atrophy and diabetic retinopathy.
Key points
from its scores- ✓Good share-price trend9.8
- ✓Favourable backdrop8.7
- ✕Little or no dividend0.5
- ✕Demanding valuation0.7
- ✕Little competitive advantage0.8
AI analysis
bottom line, main risk, context and newsOnly suitable for high-risk profiles who believe in the potential of its retinal candidates and accept the high probability of dilution and clinical failure.
Belite Bio is a clinical-stage biotech with no revenue or profits, a liquid balance sheet (current ratio 33.56) but negative profitability (ROE -22.10%) and a demanding valuation (forward P/E 69.06). The strong stock momentum (+119% in 12 months) contrasts with the lack of operating fundamentals, making it a high-risk, high-reward bet dependent on the success of its clinical trials.
The main risk is the failure of its clinical trials or lack of regulatory approval, which would leave the company worthless and force significant dilution to finance its continuity.
Context and risks
Clinical-stage biotech with no revenue or profits, dependent on external financing and regulatory approval of its candidates. The rise in long-term rates increases the cost of capital to finance its development, and the inherent regulatory risk of the biotech sector is high.
Is Belite Bio stock cheap or expensive?
at the analysis date| Multiple | Company | Sector | Difference |
|---|---|---|---|
| Price / book | 8.1 | 4.1 | +97% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 0.7 out of 10 (median for Healthcare: 4.7).
Average analyst target: 228.89 USD, +46.6% versus the price.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- Forward P/E
- 69.1
- Price / book
- 8.1
- Market cap
- 6.3B USD
Profitability
- ROE
- −22.1%
- ROA
- −15.7%
- Gross margin
- 0.0%
- Operating margin
- 0.0%
- Net margin
- 0.0%
Solvency
- Total debt
- 0 USD
- EBITDA
- −118.5M USD
- Current ratio
- 33.56
Growth
- EPS (TTM)
- −2.74 USD
- EPS (forward)
- 2.26 USD
Dividend
- Dividend yield
- 0.0%
Risk and market
- Beta
- −1.23
- Analyst consensus
- none (9)
- Target price
- 228.89 USD
- 52-week range
- 76.50 – 200.00
Recent news
All BLTE news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Belite Bio
Is Belite Bio stock cheap or expensive?
Valuation score: 0.7 out of 10 (median for Healthcare: 4.7). Average analyst target: 228.89 USD, +46.6% versus the price. This is not investment advice.
What score does Belite Bio get on MeridIAn Screener?
It scores 3.2 out of 10, rank 2,053 of 2,130 (better than 3% of the companies analysed). Its strongest category is Momentum (9.8) and its weakest, Dividend (0.5). Analysis of 08/10/2026.
How much is Belite Bio worth on the stock market?
Its market capitalisation is 6.3B USD.
Does Belite Bio pay a dividend?
It pays no dividend, or almost none.
How has Belite Bio stock performed over the last year?
It has risen 96.9% over the last year, excluding dividends. Over the last 52 weeks it has traded between 76.50 and 200.00 USD. Past performance does not guarantee future results.
What do analysts think of Belite Bio?
9 analysts cover it; their average recommendation is “none” and their average target is 228.89 USD (+46.6% versus the price). It is an estimate, not market data.